Post Content
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best growth stocks to buy according to billionaires.
As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy consensus on Wall Street. Based on 21 analyst targets, the average price target stood at $89.00, with a high target of $110.00 and a low target of $39.00. Using the share price in that March 13 snapshot, the average target implied roughly 25% upside.
Likoper/Shutterstock.com
The bullish stance came as Ionis entered 2026 with a fuller commercial and pipeline story than a simple rating change might suggest. On February 25, 2026, the company reported full-year 2025 revenue of $944 million, up 34% from 2024, helped by the commercial launch of TRYNGOLZA and a $280 million upfront payment from Ono Pharmaceutical. Ionis also said it expects 2026 revenue of $800 million to $825 million on a like-for-like basis and ended 2025 with $2.7 billion in cash, cash equivalents, and short-term investments.
Management then added more context at investor conferences in March. At the TD Cowen conference on March 2, 2026, Ionis said TRYNGOLZA had received priority review for severe hypertriglyceridemia, with a June 30, 2026, PDUFA date, and indicated that 2026 guidance for the product could be updated after the first quarter. At the Leerink conference on March 9, 2026, the company said TRYNGOLZA generated $108 million in 2025 revenue and projected U.S. peak sales above $2 billion. Ionis also pointed to several 2026 catalysts, including Phase 3 readouts tied to CARDIO-TTRansform and Novartis-partnered pelacarsen in HORIZON. At the Barclays conference on March 11, 2026, management again described 2026 as a transformational year with multiple launches, approvals, and late-stage readouts ahead.
Against that backdrop, Leerink analyst Mani Foroohar maintained an Outperform rating on March 3, 2026, and raised his price target to $104 from $102.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a biotechnology company focused on discovering and developing RNA-targeted medicines for serious diseases. The company says its platform is built around advancing treatments across neurology, cardiology, and other specialty areas.
While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.